期刊
TRENDS IN GENETICS
卷 29, 期 8, 页码 488-497出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tig.2013.05.005
关键词
mitochondrial disease; gene therapy; Leber hereditary optic neuropathy
资金
- Science Foundation Ireland
- Health Research Board of Ireland
- Fighting Blindness Ireland
- Foundation Fighting Blindness USA (NNRI)
- Wellcome Trust
- European framework programme EviGenoRet
- Enterprise Ireland
It has become evident that many human disorders are characterised by mitochondrial dysfunction either at a primary level, due to mutations in genes whose encoded products are involved in oxidative phosphorylation, or at a secondary level, due to the accumulation of mitochondrial DNA (mtDNA) mutations. This has prompted keen interest in the development of cell and animal models and in exploring innovative therapeutic strategies to modulate the mitochondrial deficiencies observed in these diseases. Key advances in these areas are outlined in this review, with a focus on Leber hereditary optic neuropathy (LHON). This exciting field is set to grow exponentially and yield many candidate therapies to treat this class of disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据